<DOC>
	<DOCNO>NCT01449682</DOCNO>
	<brief_summary>To test efficacy 0.7 mg intravitreal dexamethasone implant ( Ozurdex® ) macular function recalcitrant macular edema associate retinal vein occlusion follow treatment 2 prior intravitreal anti-VEGF drug injection .</brief_summary>
	<brief_title>Efficacy Intravitreal DEX Implant Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections .</brief_title>
	<detailed_description>The efficacy DEX implant macular edema RVO well establish multiple clinical trial . However , duration frequency re-treatment extensively explore . In addition , prior study test efficacy DEX implant retinal macular function use diagnostic test measurement multi-focal ERG , microperimetry RAM testing . Since VA OCT outcomes always correlate , assessment ( mf-ERG , microperimetry , RAM test ) may useful early predictor patient retreat . This study assess 2 group ( 0.7mg PRN 0.7mg Q16 week ) assess high resolution OCT , RAM testing , microperimetry , Multi-focal ERG outcome . For PRN group retreat base fluid OCT , investigate microperimetry multifocal ERG change would earlier predictor fluid returning .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Presence central retinal vein occlusion ( CRVO ) branch retinal vein occlusion ( BRVO ) Prior treatment &gt; = 2 intravitreal antiVEGF injection treatment last 45 day . Age 18 year old ETDRS Visual acuity 3 72 letter approximate Snellen equivalent 20/25 20/800 Central foveal thickness &gt; 275 micron presence cystic edema OCT study . For sexually active woman childbearing potential , agreement use appropriate form contraception ( abstinence ) duration study . Ability provide write informed consent • Capable comply study protocol History steroidrelated glaucoma ( steroid response ) require one topical glaucoma medication . Intraocular injection steroid medication within prior 4 month Evidence significant retinal ischemia fluorescein angiography opinion treat physician . Previous laser photocoagulation within 4 month study Concurrent ocular disease ( e.g proliferative diabetic retinopathy , geographic atrophy ) would limit visual acuity opinion treat physician Patients pregnant . Unwilling unable follow comply study related procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>BRVO</keyword>
	<keyword>CRVO</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Anti-VEGF</keyword>
	<keyword>Ozurdex</keyword>
</DOC>